In an interview with PharmaShots, Mark Gurney, CEO at Tetra Therapeutics shared his views on the results of the P-II exploratory study of BPN14770 in adult patients with Fragile X […]readmore
Tags : BPN14770
Shots: The P-II study is a two-way crossover study assessing BPN14770 (25mg, bid) vs PBO in 30 adult male patients aged 18-45yrs. with FXS due to >200 CGG repeats in […]readmore
Shots: The companies collaborate to develop and commercialize BPN14770 for AD, Fragile X syndrome and other indications marked by cognitive and memory deficits. Shionogi has increased its equity investment in […]readmore